Our team has a wealth of experience and expertise in the development of protein/peptide therapeutics and an in-depth understanding of the needs of the pharmaceutical industry when it comes to the development and manufacture of novel, effective and safe biologics. In addition, with our business acumen and experience of forming strategic alliances we are working to build effective partnerships to deliver biologics solutions:
Dr Sam Williams | Non-Exec Chairman
Sam became Chairman of Glythera in May 2016. Sam brings 18 years' experience in the biotechnology industry to the Board, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and chief executive. Sam is the founding CEO of Modern Biosciences (MBS), a London-based company development treatments for autoimmune diseases, and also oversees the biotechnology portfolio of IP Group plc. He is a board member of Diurnal Group plc, C4X Discovery Holdings Plc and the UK BioIndustry Association (BIA), and serves on the Translational Awards Advisory Committee of the British Heart Foundation (BHF). Sam has a PhD in molecular biology from Cambridge University and a degree in Biology from Oxford University.